Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?

ABSTRACT: Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Due to its heterogeneity and lack of hormone receptor expression, this subtype is more likely to metastasize and resist treatment attempts than are other forms of breast cancer. Due to the absence of targetable receptors, chemotherapy and breast conserving surgery have been the predominant treatment options for patients. However, resistance to chemotherapy and local recurrence of the tumors is frequent. Emerging immunotherapies have begun to change treatment plans for patients diagnosed with TNBC. In this review, we discuss the various immune pathways identified in TNBC and the role they play as targets for new potential treatment choices. Various therapeutic options that inhibit key pathways in cellular gro

SUBMITTER: Newton EE 

PROVIDER: S-EPMC8833442 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature